Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Non-Current Debt: 2010-2024

Historic Non-Current Debt for UNITED THERAPEUTICS (UTHR) over the last 9 years, with Jun 2024 value amounting to $100.0 million.

  • UNITED THERAPEUTICS's Non-Current Debt fell 87.50% to $100.0 million in Q2 2024 from the same period last year, while for Jun 2024 it was $100.0 million, marking a year-over-year decrease of 87.50%. This contributed to the annual value of $300.0 million for FY2023, which is 62.50% down from last year.
  • Per UNITED THERAPEUTICS's latest filing, its Non-Current Debt stood at $100.0 million for Q2 2024, which was down 50.00% from $200.0 million recorded in Q1 2024.
  • UNITED THERAPEUTICS's Non-Current Debt's 5-year high stood at $800.0 million during Q1 2020, with a 5-year trough of $100.0 million in Q2 2024.
  • Its 3-year average for Non-Current Debt is $590.0 million, with a median of $800.0 million in 2023.
  • Its Non-Current Debt has fluctuated over the past 5 years, first soared by 33.33% in 2020, then slumped by 87.50% in 2024.
  • Quarterly analysis of 5 years shows UNITED THERAPEUTICS's Non-Current Debt stood at $800.0 million in 2020, then remained steady at $800.0 million in 2021, then remained steady at $800.0 million in 2022, then slumped by 62.50% to $300.0 million in 2023, then tumbled by 87.50% to $100.0 million in 2024.
  • Its last three reported values are $100.0 million in Q2 2024, $200.0 million for Q1 2024, and $300.0 million during Q4 2023.